Scholar Rock Holding (SRRK) Cash from Operations (2017 - 2026)
Scholar Rock Holding (SRRK) recorded quarterly Cash from Operations of 82101000.0 in Q1 2026, down 8.75% quarter-over-quarter from 75496000.0 in Q4 2025, and down 4.35% on a YoY basis from 85838963.64 in Q1 2025.
Scholar Rock Holding (SRRK) Cash from Operations (2017 - 2026) Analysis & Trends
Scholar Rock Holding's Cash from Operations history runs 10 years deep, the most recent figure standing at 82101000.0 for Q1 2026.
- In Q1 2026, Cash from Operations fell 4.35% year-over-year to 82101000.0; the TTM figure through Mar 2026 stood at 303461000.0 (down 32.03% YoY), while the FY2025 annual figure was 300035000.0, down 49.31% from the prior year.
- Cash from Operations was 82101000.0 for Q1 2026 at Scholar Rock Holding, down from 75496000.0 in the prior quarter.
- In the past five years, Cash from Operations ranged from a high of 26483000.0 in Q3 2022 to a low of 82101000.0 in Q1 2026.
- Historically, Cash from Operations has averaged 50647352.94 across 5 years, with a median of 49196000.0 in 2024.
- The sharpest annual moves came in 2022 and 2024: Cash from Operations increased 26.39% in 2022, then sank 62.54% in 2024.
- A 5-year view of Cash from Operations shows it stood at 28907000.0 in 2022, then slipped by 29.2% to 37349000.0 in 2023, then slumped by 32.57% to 49513000.0 in 2024, then tumbled by 52.48% to 75496000.0 in 2025, then declined by 8.75% to 82101000.0 in 2026.
- The last three Cash from Operations figures came in at 82101000.0 (Q1 2026), 75496000.0 (Q4 2025), and 68923000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -1.67 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -12.20 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -2.49 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.43 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Scholar Rock Holding | 6.03 Bn | 5.55 Bn | - | -82.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -82.10 Mn |
| Mar 31, 2026 | -82.10 Mn |
| Dec 31, 2025 | -75.50 Mn |
| Dec 31, 2025 | -75.50 Mn |
| Sep 30, 2025 | -68.92 Mn |
| Sep 30, 2025 | -68.92 Mn |
| Jun 30, 2025 | -76.94 Mn |
| Jun 30, 2025 | -76.94 Mn |
| Mar 31, 2025 | -78.68 Mn |
| Mar 31, 2025 | -78.68 Mn |
| Dec 31, 2024 | -49.51 Mn |
| Dec 31, 2024 | -49.51 Mn |
| Sep 30, 2024 | -52.46 Mn |
| Sep 30, 2024 | -52.46 Mn |
| Jun 30, 2024 | -49.20 Mn |
| Jun 30, 2024 | -49.20 Mn |
| Mar 31, 2024 | -49.79 Mn |
| Mar 31, 2024 | -49.79 Mn |
| Dec 31, 2023 | -37.35 Mn |
| Dec 31, 2023 | -37.35 Mn |